Vertex Pharmaceuticals Claims Top Trading Spot as FDA Expands Casgevy Approval to Younger Patients

Market Snapshot

Vertex Pharmaceuticals Incorporated (VRTX) experienced a period of heightened trading activity on July 1, 2026, despite a relatively modest price adjustment. The biotechnology firm recorded a trading volume of $0.72 billion, marking it as the most actively traded stock in the U.S. market for the day. This significant liquidity suggests intense investor interest, likely driven by the release of major regulatory developments. Throughout the session, the stock closed with a slight gain, rising 0.26%. While the percentage change was marginal, the volume ranking indicates that market participants were actively repositioning in response to fresh news. The stock currently trades with a market capitalization of approximately $126.07 billion, reflecting its status as a major player in the global biotech sector. Technical indicators show the stock trading below its 200-day moving average of $455.05 and its 50-day moving average of $444.56, though it remains well above its 52-week low of $362.50. The company’s valuation metrics include a price-to-earnings ratio of 29.46 and a beta of 0.30, suggesting lower volatility relative to the broader market compared to its recent earnings momentum, which saw it beat analyst estimates in the previous quarter with $4.47 earnings per share.

Key Drivers

The primary catalyst for the trading volume and market attention on July 1 was the U.S. Food and Drug Administration’s approval of an expanded indication for Vertex’s gene therapy, Casgevy. The FDA granted supplemental approval for the treatment, known generically as exagamglogene autotemcel, for patients as young as two years old. Previously, Casgevy was approved for individuals aged 12 and older with sickle cell disease or transfusion-dependent beta thalassemia. This expansion marks a historic milestone, as it is the first gene therapy approved for sickle cell disease patients in this younger age group. The approval addresses a critical unmet medical need, allowing pediatric patients to access a transformative one-time treatment earlier in life, potentially before cumulative organ damage occurs.

The regulatory process for this approval was notably expedited, highlighting the urgency and priority assigned to this therapy by federal health authorities. The FDA completed its review in just 53 days following the filing, utilizing the Commissioner’s National Priority Voucher pilot program. This fast-track mechanism is designed to shorten review times for drugs addressing significant health priorities. The approval is only the eighth selected under this specific pilot program, underscoring the government’s commitment to accelerating access to innovative treatments for rare and severe diseases. This rapid turnaround signals strong regulatory confidence in the safety and efficacy profile of the treatment for younger demographics.

Clinical data supporting the expansion demonstrated robust efficacy across different age cohorts. In trials involving children aged five to under 12 with sickle cell disease, all eight evaluable patients experienced no severe vaso-occlusive crises or painful episodes for at least 12 consecutive months within the first 24 months of infusion. For patients with beta thalassemia, eight of nine evaluable children achieved transfusion independence for 12 consecutive months, with a median duration of 20.1 months. These results reinforce the consistency of Casgevy’s benefits across age groups, validating the therapy’s potential to deliver durable, transformative outcomes for patients who have historically had limited treatment options.

From a commercial perspective, this approval significantly expands the addressable patient population in the United States. Approximately 5,500 additional children are now eligible for this established one-time therapy, broadening the market beyond the previously approved 12-and-older demographic. Vertex has already established a robust infrastructure to support this expansion, with more than 75 authorized treatment centers activated across the U.S. These centers are designed to facilitate patient access and manage the complex logistics associated with gene therapy administration, including myeloablative conditioning and stem cell infusion.

The company’s leadership emphasized the strategic importance of this development in the context of their broader mission. Vertex CEO Reshma Kewalramani noted that just as the company redefined care for cystic fibrosis, it aims to transform the future for those living with sickle cell disease and beta thalassemia. The approval allows clinicians to consider treatment before years of cumulative damage from these life-shortening diseases take hold. Sickle cell disease, for instance, carries an estimated lifetime healthcare cost of $4–6 million per patient, while beta thalassemia can cost $5–5.7 million, highlighting the economic and human impact of earlier intervention.

Looking ahead, Vertex is actively pursuing further global expansion of this indication. Regulatory review for the label expansion is currently underway in the Kingdom of Saudi Arabia and the United Kingdom, with submissions aimed at extending the indication to children as young as five in those jurisdictions. The company continues to advance long-term follow-up studies, such as CLIMB-131, to evaluate the safety and efficacy of Casgevy over a 15-year period. These ongoing efforts, combined with the recent FDA approval, position Vertex to solidify its leadership in the gene therapy space and drive long-term value creation for shareholders.